Vaccibody AS
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of local… Read more
Vaccibody AS (5VB) - Total Liabilities
Latest total liabilities as of September 2025: €6.45 Million EUR
Based on the latest financial reports, Vaccibody AS (5VB) has total liabilities worth €6.45 Million EUR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Vaccibody AS - Total Liabilities Trend (2018–2024)
This chart illustrates how Vaccibody AS's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Vaccibody AS Competitors by Total Liabilities
The table below lists competitors of Vaccibody AS ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Go Hub Capital Berhad
KLSE:0311
|
Malaysia | RM26.11 Million |
|
Skyharbour Resources Ltd
OTCQX:SYHBF
|
USA | $731.35K |
|
Banestes S.A - Banco do Estado do Espírito Santo
SA:BEES3
|
Brazil | R$36.68 Billion |
|
China Everbright Greentech Limited
F:CK7
|
Germany | €25.30 Billion |
|
InspireMD Inc
NASDAQ:NSPR
|
USA | $14.36 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩9.84 Billion |
|
Index Living Mall Public Company Limited
BK:ILM
|
Thailand | ฿6.70 Billion |
Liability Composition Analysis (2018–2024)
This chart breaks down Vaccibody AS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 17.14 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vaccibody AS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vaccibody AS (2018–2024)
The table below shows the annual total liabilities of Vaccibody AS from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €17.27 Million | -53.24% |
| 2023-12-31 | €36.93 Million | -42.71% |
| 2022-12-31 | €64.46 Million | -9.85% |
| 2021-12-31 | €71.50 Million | +39.71% |
| 2020-12-31 | €51.18 Million | +1795.30% |
| 2019-12-31 | €2.70 Million | -4.75% |
| 2018-12-31 | €2.83 Million | -- |